Spark Therapeutics was founded in 2013 and became a Member of the Roche Group in 2019.

The organisation is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including inherited retinal disorders, haemophilia, lysosomal storage disorders and neurodegenerative diseases.

Spark Therapeutics is comprised of over 800 employees with its headquarters situated in Philadelphia, USA.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.